Skip to main content
Pacira BioSciences, Inc. logo

Pacira BioSciences, Inc. — Investor Relations & Filings

Ticker · PCRX ISIN · US6951271005 LEI · 549300P56LERYBDHCF69 US Manufacturing
Open in API
Filings indexed 1,217 across all filing types
Latest filing 2018-05-03 Earnings Release
Country US United States of America
Listing US PCRX

About Pacira BioSciences, Inc.

https://www.pacira.com/

Pacira BioSciences, Inc. is a pharmaceutical company that develops, commercializes, and manufactures non-opioid pain management and regenerative health solutions. The company's mission is to provide alternatives to opioids by delivering innovative, precise, and targeted therapies. Its products and research pipeline address a diverse range of needs, including postsurgical, chronic, and musculoskeletal pain. Pacira is also focused on developing advanced solutions, including gene therapy, to address unmet needs in pain management.

Recent filings

Filing Released Lang Actions
8-K
Earnings Release Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated May 3, 2018, reporting the results of operations and financial condition for the first quarter ended March 31, 2018. It specifically mentions that the full text of the earnings press release is furnished as an exhibit (Exhibit 99.1). The document itself is only 3300 characters long and primarily serves to announce the earnings release rather than containing detailed financial statements or substantive financial data. According to the 'Menu vs Meal' rule, such a short document that announces and attaches an earnings press release should be classified as an Earnings Release (ER) because it is the initial announcement of quarterly financial results. The document is not a full quarterly report (IR) nor a certification or regulatory filing (RNS). Therefore, the appropriate classification is Earnings Release (ER) with high confidence.
2018-05-03 English
DEF 14A
Proxy Solicitation & Information Statement
2018-04-27 English
SCHEDULE 13G
Major Shareholding Notification
2018-04-16 English
8-K
Board/Management Information Classification · 100% confidence The document is a Form 8-K filed with the SEC, dated March 27, 2018, reporting the departure of a Chief Operating Officer and the assumption of his duties by the CEO. The key section is Item 5.02, which relates to changes in directors or certain officers. There is no financial data or report attached, and the content focuses solely on management changes. According to the filing definitions, announcements of changes in the company's board of directors or senior management fall under Board/Management Information (MANG). The document length is short and does not contain financial statements or other report types. Therefore, the correct classification is MANG with high confidence.
2018-03-29 English
10-K
Annual Report FY 2017
2018-02-28 English
8-K
Earnings Release Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated February 28, 2018, by Pacira Pharmaceuticals, Inc. It specifically mentions Item 2.02, which is "Results of Operations and Financial Condition," and states that a press release announcing the fourth quarter and full-year 2017 results is furnished as Exhibit 99.1. The document text itself is the 8-K filing that includes the earnings press release but does not contain detailed financial statements or comprehensive analysis. The length is 3296 characters, which is relatively short and consistent with an earnings release announcement rather than a full report. The document is primarily an initial announcement of quarterly and annual financial results, which fits the definition of an Earnings Release (ER).
2018-02-28 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.